KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Share-based Compensation (2016 - 2025)

Pacira BioSciences has reported Share-based Compensation over the past 16 years, most recently at $13.5 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $13.5 million for Q4 2025, up 10.05% from a year ago — trailing twelve months through Dec 2025 was $57.5 million (up 12.37% YoY), and the annual figure for FY2025 was $57.5 million, up 12.37%.
  • Share-based Compensation for Q4 2025 was $13.5 million at Pacira BioSciences, down from $14.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for PCRX hit a ceiling of $15.5 million in Q2 2025 and a floor of $10.1 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $12.5 million (2023), compared with a mean of $12.3 million.
  • Biggest five-year swings in Share-based Compensation: fell 5.1% in 2023 and later grew 23.54% in 2025.
  • Pacira BioSciences' Share-based Compensation stood at $10.9 million in 2021, then grew by 16.41% to $12.7 million in 2022, then fell by 2.03% to $12.4 million in 2023, then decreased by 1.24% to $12.3 million in 2024, then grew by 10.05% to $13.5 million in 2025.
  • The last three reported values for Share-based Compensation were $13.5 million (Q4 2025), $14.0 million (Q3 2025), and $15.5 million (Q2 2025) per Business Quant data.